Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00955942 | Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy | terminated | Phase 1 | 48 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Apr 1, 2020 |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516 | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 0 | Mar 18, 2020 | clinicaltrials |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | terminated | Phase 1 | 23 | University of Maryland, BaltimoreOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT01562210 | Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC(olaparib) | completed | Phase 1 | 28 | The Netherlands Cancer InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 17 | Regeneron PharmaceuticalsINDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT00097903 | Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer | completed | Phase 1 | 32 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 | 28 | AbbVieINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02946671 | Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients | completed | Phase 1 | 16 | Osaka UniversityOTHER | 1 | Mar 6, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02916745 | Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer | completed | Phase 1 | 5 | Concordia Laboratories Inc.INDUSTRY | 2 | Mar 4, 2020 | clinicaltrials |
| NCT03130881 | Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC. | unknown | Phase 1 | 60 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02840994 | A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 | 24 | Bavarian NordicINDUSTRY | 1 | Feb 27, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin(iTRAP) | withdrawn | Phase 1 | 0 | Queen Mary University of LondonOTHER | 0 | Feb 25, 2020 | clinicaltrials |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | terminated | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 24, 2020 | clinicaltrials |
| NCT02009436 | Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | completed | Phase 1 | 8 | Albert Einstein College of MedicineOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02563548 | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors | completed | Phase 1 | 56 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02048917 | Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies | completed | Phase 1 | 93 | University of KentuckyOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03344861 | Safety of PDT-Photofrin® Prior to Lung Surgery | completed | Phase 1 | 10 | Concordia Laboratories Inc.INDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT01310244 | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 23 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | terminated | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01918761 | Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 5 | Central European Cooperative Oncology GroupOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT00036790 | Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT04201990 | Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer(CCA-MPLC) | unknown | Phase 1 / Phase 2 | 20 | ShiYue LiOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00214123 | Hypofractionated Radiotherapy for Lung Cancer | completed | Phase 1 | 79 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | terminated | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01258868 | Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT01059552 | Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)(NSCLC) | completed | Phase 1 | 18 | Fox Chase Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00923273 | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02896231 | First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001 | completed | Phase 1 | 37 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04175158 | Clinical Trial in Chinese Healthy Volunteers of GB222 | unknown | Phase 1 | 84 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00581789 | Erlotinib and Sunitinib in NSCLC | completed | Phase 1 | 11 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2020source: clinicaltrials